SNRIs
High-yield Verified · Oct 2026Prototype: venlafaxine
SNRIs are a class of medications used for major depressive disorder and generalized/social anxiety.
Serotonin-norepinephrine reuptake inhibitors — the SSRI’s dual-action cousin, useful in depression and chronic pain.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 Adding a second neurotransmitter
SSRIs (see that page) lift mood by raising serotonin alone. SNRIs go one step further: they block the reuptake of both serotonin (SERT) and norepinephrine (NET), so two mood-and-pain neurotransmitters build up in the synapse. That dual action gives them a second, distinctive use — because norepinephrine (and serotonin) also dampen pain signals in the spinal cord, SNRIs — duloxetine in particular — treat neuropathic pain (diabetic neuropathy) and fibromyalgia in addition to depression and anxiety.
Like all antidepressants, the mood benefit is delayed — it typically begins within 2–4 weeks, and noticeable mood change commonly takes 4–8 — and, like the SSRIs, they carry the class boxed warning for suicidality in patients under 25 during early treatment.
02 The two nursing themes — blood pressure and discontinuation
The norepinephrine (sympathetic) effect is thought to explain a signature adverse effect: blood-pressure increases — greatest with venlafaxine, where they are dose-related — so blood pressure is monitored. (Duloxetine and desvenlafaxine also need BP checks.) Combining an SNRI with other serotonergic drugs (SSRIs, MAOIs, triptans, tramadol, St. John’s wort) risks serotonin syndrome.
The second theme is discontinuation syndrome: stopping abruptly causes dizziness, "brain zaps" (shock-like sensations), flu-like symptoms, and irritability — withdrawal is more common with short-half-life antidepressants such as venlafaxine (half-life about 5 hours). SNRIs must be tapered, never stopped cold.
Drug names
Indications
- Major depressive disorder & generalized/social anxiety, panic disorder
- Neuropathic pain: diabetic neuropathy, fibromyalgia, chronic musculoskeletal pain (duloxetine)
Mechanism of action
Inhibit reuptake of both serotonin (SERT) and norepinephrine (NET), increasing their synaptic availability — improving mood/anxiety and, through descending inhibitory pain pathways, relieving neuropathic pain. Norepinephrine reuptake block is thought to underlie the blood-pressure effect.
Therapeutic effects — what you'll see working
Mood benefit typically begins within 2–4 weeks and builds over 4–8 (assess adherence and suicidality early); with duloxetine some pain relief can appear as early as week 1. The dual mechanism means monitoring both psychiatric response and blood pressure.
- Improved mood & anxiety
- Raising serotonin and norepinephrine relieves depression and anxiety over weeks, comparable to SSRIs.
- Neuropathic pain relief
- Enhanced descending inhibition in the spinal cord reduces diabetic-neuropathy and fibromyalgia pain — duloxetine is FDA-approved for both.
Adverse effects
The serotonin effects mirror SSRIs (GI, sexual, serotonin syndrome); the added norepinephrine effect brings hypertension and activation. Discontinuation is the practical pitfall.
Interactions
Contraindications
The contraindications are the serotonergic-combination dangers and the states worsened by added norepinephrine.
When to hold
Assess before giving — these findings mean hold the dose and act.
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Common questions
What are SNRIs used for?
How do SNRIs work?
What are the serious side effects of SNRIs?
When should a nurse hold SNRIs, and what safety checks apply?
Conditions treated
"Duloxetine is another medication that has been showing some positive results."
First-line alongside SSRIs, not a fallback. In generalized anxiety, SSRIs and SNRIs together are named first-line, with duloxetine and venlafaxine extended-release among the specific first-line agents. In PTSD, do not file venlafaxine under "off-label alternative." VA/DoD 2023 recommends paroxetine, sertraline OR venlafaxine (Rec 15, STRONG for) — venlafaxine sits inside the first-line recommendation at full strength, alongside the two SSRIs, even though the FDA clearance belongs to the SSRIs. Other agents in the class have no strong evidence differentiating them. The disorder-side reasoning is the same mechanism statement that drives the SSRI role: the serotonin and noradrenergic systems are the common pathways involved in anxiety, and an agent acting on both is a rational first choice rather than a second-tier one. The monitoring point that separates SNRIs from SSRIs on a nursing page is blood pressure — the Depression page carries the sourced caution to check it before starting and routinely thereafter, and it applies here unchanged. The class page owns the pharmacology.
Efficacy comparable to SSRIs — the alternative when an SSRI fails, and a deliberate first pick when depression coexists with pain: duloxetine is FDA-approved for diabetic neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Disorder-side caution: SNRIs can raise blood pressure — check BP before starting and routinely after.
First-line, especially with fatigue or depression. "SNRIs, such as duloxetine and milnacipran, are appropriate for patients with significant fatigue or depression associated with fibromyalgia" (StatPearls). Both are FDA-labeled: CYMBALTA for "Fibromyalgia (FM) in adults and pediatric patients 13 years of age and older"; "SAVELLA is indicated for the management of fibromyalgia" and "is not approved for use in the treatment of major depressive disorder." Boxed suicidality warning; no MAOIs; taper to stop; SAVELLA raises BP and heart rate; CYMBALTA can cause hepatic failure.
Duloxetine — second-line for chronic low back pain (ACP: "tramadol or duloxetine as second-line therapy"); SNRIs "are more effective than placebo for nonspecific chronic low-back pain."
Prevention: venlafaxine, especially with depression or anxiety. With a triptan, watch for serotonin syndrome.
Adjuvant for neuropathic pain. StatPearls: neuropathic pain may respond better to serotonin-norepinephrine reuptake inhibitors such as duloxetine than to NSAIDs like ibuprofen in acute injuries. HHS also lists TCAs and SNRIs.
[Duloxetine] FDA-indicated for "Diabetic peripheral neuropathic pain (DPNP) in adults." Boxed warning: antidepressants "increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults." "Orthostatic hypotension, falls, and syncope have been reported" — most often in the first week or after dose increases. Stop for jaundice or liver dysfunction and avoid "in patients with substantial alcohol use or evidence of chronic liver disease"; watch for serotonin syndrome; "Monitor blood pressure prior to initiating treatment and periodically"; in DPNP patients, increases in fasting glucose and HbA1c have been observed. "A gradual reduction in dosage rather than abrupt cessation is recommended." Venlafaxine is a second-line SNRI (StatPearls, relaying a 2022 review).
See also
Potent pain control via µ-opioid receptor agonism. Watch for respiratory depression; reverse with naloxone.
Potentiate GABA for anxiety, seizures, and sedation. Additive CNS depression — deadly with opioids.
First-line antidepressants that raise synaptic serotonin. Delayed onset; watch for serotonin syndrome and early suicidality.
Stabilize neuronal firing to prevent seizures. Many are narrow-therapeutic-index — level monitoring and rash vigilance are essential.
A widely used fever/pain reliever with no anti-inflammatory or platelet effect — but hepatotoxic in overdose.
Dopamine-blocking drugs for psychosis. Watch EPS, NMS, metabolic effects — boxed warning in elderly dementia.
Sources
- Venlafaxine — SNRI mechanism, hypertension, discontinuation — StatPearls (NCBI)
- Duloxetine — dual reuptake, neuropathic pain, hepatotoxicity — StatPearls (NCBI)
- Effexor XR (venlafaxine) — boxed warning, blood pressure, discontinuation (FDA label) — FDA / DailyMed
- Cymbalta (duloxetine) — pain indications, hepatotoxicity, angle-closure glaucoma (FDA label) — FDA / DailyMed
- Pristiq (desvenlafaxine) — FDA label — FDA / DailyMed
- Open RN Mental Health 2e — Ch. 6 Psychotropic Medications (antidepressants, serotonin syndrome) — Open RN (NCBI Bookshelf)
- Serotonin Syndrome — StatPearls (NCBI)
- Norepinephrine — alpha-1 vasoconstriction — StatPearls (NCBI)
- Desvenlafaxine — StatPearls (NCBI)
- NP Safe Prescribing of Controlled Substances — SNRIs for chronic and neuropathic pain — StatPearls (NCBI)
- Amitriptyline — antidepressant onset (2–4 weeks) — StatPearls (NCBI)
- Calvi et al. 2021 — Antidepressant drugs effects on blood pressure (Front Cardiovasc Med, CC BY) — Frontiers in Cardiovascular Medicine (PMC, CC BY 4.0)
- Therapeutics Letter — antidepressant withdrawal (UBC Therapeutics Initiative, CC BY) — Therapeutics Initiative, University of British Columbia (NCBI Bookshelf, CC BY)
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.